EGFR and non-small cell lung carcinoma: The first evidence of this derived from Hashida S and colleagues’ work, whom investigated the EGFR-TKI resistance mechanisms in a total of 10 afatinib-resistant cell lines from parental NSCLC cells with activating EGFR mutations (83).